Human prostate cancer cells, depleted of perlecan and grafted in mice, produced tumors of decreased size and vascularization, where the effects were correlated to reduced secretion of VEGF-A in the xenografts (193). The gene discussed is HSPG2; the disease is prostate carcinoma.